A Mississauga-based biotech firm has received $200 million in federal funds to build a new COVID-19 vaccine manufacturing facility within the city.
The funding was announced Tuesday morning — bringing a “made-in-Canada” solution for vaccine production in Peel Region. Resilience Biotechnologies Inc., a subsidiary of National Resilience Inc., specializes in vaccine manufacturing, development and assembly, and will use the funding to expand its facility
with a 45,000 square-foot upgrade, as well as add 205 new full-time jobs as it ramps up production in the fight against COVID- 19.
“(This) investment will not only boost Canadian manufacturing, it will also support good manufacturing jobs,” said Prime Minister Justin Trudeau, speaking alongside Innovation
Minister François- Philippe Champagne during an online press conference. “To rebuild from this pandemic, we’re investing in Canada.”
The facility will produce anywhere from 112 – 640 million doses of vaccine per year once the facility upgrades are complete, said Resilience CEO Rahul Singh.
“Resilience was founded during the pandemic to build a better system for manufacturing complex medicines to fight deadly diseases… will help prepare Canada for future pandemics
and strengthen the country’s biopharmaceutical ecosystem.